Cancer with its rising prevalence globally, has managed to become the second most common cause of death worldwide. The threat it imposes is exacerbated by the failure of anti-tumor drugs and emergence of drug resistance, hence the need for the development of new potent anti-tumor molecules with lower side effects. Despite the recent introduction of several promising novel therapies that have shown considerable therapeutic success including hormone therapy, radiotherapy, and chemotherapy such as the drugs; Sorafenib and Lenvatinib, drug resistance and serious side effects remain the major challenges in cancer treatment.
Based on the aforementioned aspects, new curative therapeutic strategies are urgently needed that overcome the anticancer therapy resistance and have superior efficacy, lower toxicity as well as better selectivity. The advances in molecular biology, genetics, and protein kinase studies have improved the identification of molecular targets unique to cancer cells or those overexpressed on them. The design and synthesis of new synthetic agents affecting these targets promise the development of more selective anticancer drugs with less toxic side effects.
The aim of this research topic is to highlight the recent progress in cancer treatment .This is achieved through the design and synthesis of small heterocyclic molecules which are highly selective to different molecular genetics and proteins in the cancer cells, all with the added benefit of overcoming drug resistance and fewer side effects.
The submission of Original Research, Mini Review, and Review articles which concentrate on the following sub-topics will be welcomed:
• Synthesis of heterocyclic compounds using different facile and ecofriendly approaches such as ultrasound, microwave, and ball mill technique etc.
• Synthesis of heterocyclic compounds as kinase inhibitors of potential activity against different types of cancer.
• In-silico studies of heterocyclic compounds to identify and validate molecular targets in cancer treatment.
• Modifying and developing drugs of long-acting and sustained-release activity against cancer.
• Discovery of new nano formulations of heterocyclic agents for cancer treatment.
• Studying the effect of heterocyclic compounds upon various molecular markers aimed at the treatment of cancer.
• In vivo radiolabeling and biodistribution studies of small heterocyclic molecules targeting the treatment of cancer.
• Recent discoveries of heterocyclic-based compounds in molecular pharmacology and precision medicine for cancer treatment.
• Clinical diagnosis, treatment, and imaging of tissue space-occupying lesions.
• Clinical application of new drugs bearing heterocyclic scaffolds.
Cancer with its rising prevalence globally, has managed to become the second most common cause of death worldwide. The threat it imposes is exacerbated by the failure of anti-tumor drugs and emergence of drug resistance, hence the need for the development of new potent anti-tumor molecules with lower side effects. Despite the recent introduction of several promising novel therapies that have shown considerable therapeutic success including hormone therapy, radiotherapy, and chemotherapy such as the drugs; Sorafenib and Lenvatinib, drug resistance and serious side effects remain the major challenges in cancer treatment.
Based on the aforementioned aspects, new curative therapeutic strategies are urgently needed that overcome the anticancer therapy resistance and have superior efficacy, lower toxicity as well as better selectivity. The advances in molecular biology, genetics, and protein kinase studies have improved the identification of molecular targets unique to cancer cells or those overexpressed on them. The design and synthesis of new synthetic agents affecting these targets promise the development of more selective anticancer drugs with less toxic side effects.
The aim of this research topic is to highlight the recent progress in cancer treatment .This is achieved through the design and synthesis of small heterocyclic molecules which are highly selective to different molecular genetics and proteins in the cancer cells, all with the added benefit of overcoming drug resistance and fewer side effects.
The submission of Original Research, Mini Review, and Review articles which concentrate on the following sub-topics will be welcomed:
• Synthesis of heterocyclic compounds using different facile and ecofriendly approaches such as ultrasound, microwave, and ball mill technique etc.
• Synthesis of heterocyclic compounds as kinase inhibitors of potential activity against different types of cancer.
• In-silico studies of heterocyclic compounds to identify and validate molecular targets in cancer treatment.
• Modifying and developing drugs of long-acting and sustained-release activity against cancer.
• Discovery of new nano formulations of heterocyclic agents for cancer treatment.
• Studying the effect of heterocyclic compounds upon various molecular markers aimed at the treatment of cancer.
• In vivo radiolabeling and biodistribution studies of small heterocyclic molecules targeting the treatment of cancer.
• Recent discoveries of heterocyclic-based compounds in molecular pharmacology and precision medicine for cancer treatment.
• Clinical diagnosis, treatment, and imaging of tissue space-occupying lesions.
• Clinical application of new drugs bearing heterocyclic scaffolds.
